ライフサイエンスコーパス: ventricular tachycardia

1 , resuscitated cardiac arrest, and sustained ventricular tachycardia).

2 , bigeminy; 3, couplets; and 4, nonsustained ventricular tachycardia).

3 efractory ventricular fibrillation/pulseless ventricular tachycardia.

4 ssification in catecholaminergic polymorphic ventricular tachycardia.

5 on inflammation), there were 680 episodes of ventricular tachycardia.

6 and in heart failure patients with sustained ventricular tachycardia.

7 esistant ventricular fibrillation /pulseless ventricular tachycardia.

8 s had a combined history of 6577 episodes of ventricular tachycardia.

9 uided, noninvasive cardiac radioablation for ventricular tachycardia.

10 radioablation markedly reduced the burden of ventricular tachycardia.

11 ever, had more hypertrophy, and nonsustained ventricular tachycardia.

12 hythmogenic substrate and critical sites for ventricular tachycardia.

13 heter ablation of post-myocardial infarction ventricular tachycardia.

14 lie the mechanism of spontaneous polymorphic ventricular tachycardia.

15 eter ablation for post-myocardial infarction ventricular tachycardia.

16 actory ventricular fibrillation or pulseless ventricular tachycardia.

17 in premature ventricular complexes and focal ventricular tachycardia.

18 o diagnosis in catecholaminergic polymorphic ventricular tachycardia.

19 , sodium channel block alone did not prevent ventricular tachycardia.

20 compaction and catecholaminergic polymorphic ventricular tachycardia.

21 enced cardiac arrest and three non-sustained ventricular tachycardia.

22 long-cycle length TdP, and slow monomorphic ventricular tachycardia.

23 fied mice with catecholaminergic polymorphic ventricular tachycardia.

24 ured fat diet and resulted in less inducible ventricular tachycardia.

25 Among 16 critical sites for ventricular tachycardia, 3 (18%) were in a discordant re

26 a syndrome, 8; catecholaminergic polymorphic ventricular tachycardia, 3; short QT syndrome, 1; and ar

27 yndrome (13%), catecholaminergic polymorphic ventricular tachycardia (4%), arrhythmogenic right ventr

28 Of these, 177 (28.8%) had idiopathic ventricular tachycardia, 408 (66.5%) had symptomatic PVC

29 d susceptibility to induction of polymorphic ventricular tachycardia (60 vs. 24% in Kcne5(+/0) mice),

30 ophysiological procedures such as epicardial ventricular tachycardia ablation and Lariat left atrial

31 luding 104 patients who underwent epicardial ventricular tachycardia ablation and Lariat left atrial

32 rable outcomes in both Lariat and epicardial ventricular tachycardia ablation groups.

33 Ventricular tachycardia ablation is often limited by ins

34 patients undergoing epicardial access during ventricular tachycardia ablation or Lariat procedure is

35 This catheter shows promise for decreasing ventricular tachycardia ablation procedure time and impr

36 This may improve the efficacy of ventricular tachycardia ablation procedures while reduci

37 ents referred for post-myocardial infarction ventricular tachycardia ablation were included.

38 al aortic valves, who underwent scar-related ventricular tachycardia ablation, were analyzed to corre

39 sustained ventricular tachycardia, sustained ventricular tachycardia, aborted sudden cardiac death, o

40 actory ventricular fibrillation or pulseless ventricular tachycardia after at least one shock, and va

41 rhythmogenic substrate may lead to recurrent ventricular tachycardia after catheter ablation.

42 n the transient incidence of post-transplant ventricular tachycardia, although further large animal m

43 Recurrent ventricular tachycardia among survivors of myocardial in

44 es (n=2), 6 patients with noninfarct related ventricular tachycardia and 4 patients with infarct-rela

45 t QT syndrome, catecholaminergic polymorphic ventricular tachycardia and Brugada syndrome.

46 ting with ventricular tachyarrhythmias (i.e. ventricular tachycardia and fibrillation (VT, VF)) on ad

47 sk factor for sudden cardiac death caused by ventricular tachycardia and fibrillation (VT/VF).

48 diagnosed with catecholaminergic polymorphic ventricular tachycardia and his father with left ventric

49 tablished were catecholaminergic polymorphic ventricular tachycardia and long QT syndrome (17 [6%] an

50 minant role of catecholaminergic polymorphic ventricular tachycardia and long QT syndrome, especially

51 Ventricular tachycardia and premature ventricular comple

52 Catheter ablation for ventricular tachycardia and premature ventricular comple

53 l inflammation were seen in 6 patients, with ventricular tachycardia and/or cardiac arrest in 3 patie

54 Ventricular tachycardia and/or ventricular fibrillation

55 Fifty patients (60%) had ventricular tachycardia and/or ventricular fibrillation

56 Multivariable analysis retained ventricular tachycardia and/or ventricular fibrillation

57 of sinus rhythm and 33 (40%) had refractory ventricular tachycardia and/or ventricular fibrillation.

58 nic shock, post-cardiotomy shock, refractory ventricular tachycardia, and acute management of complic

59 es such as atrial fibrillation, nonsustained ventricular tachycardia, and atrioventricular block and

60 henotypes (atrial fibrillation, nonsustained ventricular tachycardia, and atrioventricular block), wh

61 lar nodal reentrant tachycardia, monomorphic ventricular tachycardia, and Brugada syndrome.

62 odynamically tolerated sustained monomorphic ventricular tachycardia, and male sex predicted lethal a

63 origin of the arrhythmic beats that initiate ventricular tachycardia, and regarding optimal therapeut

64 cally definite catecholaminergic polymorphic ventricular tachycardia are classified ambiguously as va

65 Most recurrent ventricular tachycardias are localized to regions of pri

66 l translation could improve the treatment of ventricular tachycardia arising from mid myocardial or e

67 fficacy was assessed by counting episodes of ventricular tachycardia, as recorded by ICDs.

68 Patients with sustained monomorphic ventricular tachycardia associated with coronary disease

69 ssessed as a composite end point, defined as ventricular tachycardia, bradycardia requiring device im

70 cause of their symptoms; others (monomorphic ventricular tachycardia, Brugada syndrome, torsades de p

71 actory ventricular fibrillation or pulseless ventricular tachycardia, but without proven survival ben

72 able (ventricular fibrillation and pulseless ventricular tachycardia) cardiac arrests.

73 In 2 ventricular tachycardia cases, absence of PN capture was

74 ception is the catecholaminergic polymorphic ventricular tachycardia-causing N53I substitution, which

75 mes, including catecholaminergic polymorphic ventricular tachycardia, congenital long QT syndrome, an

76 n = 16 [14%]), catecholaminergic polymorphic ventricular tachycardia (CPVT) (n = 9 [8%]), arrhythmoge

77 ssociated with catecholaminergic polymorphic ventricular tachycardia (CPVT) and atrial fibrillation (

78 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a condition of abnorma

79 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a potentially lethal g

80 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a stress-induced cardi

81 Catecholaminergic polymorphic ventricular tachycardia (CPVT) is an inherited arrhythmi

82 flecainide for catecholaminergic polymorphic ventricular tachycardia (CPVT) is unclear.

83 cause dominant catecholaminergic polymorphic ventricular tachycardia (CPVT), a leading cause of sudde

84 essive form of catecholaminergic polymorphic ventricular tachycardia (CPVT), although isolated report

85 Catecholaminergic polymorphic ventricular tachycardia (CPVT), an inherited cardiac arr

86 In catecholaminergic polymorphic ventricular tachycardia (CPVT), cardiac Purkinje cells (

87 h-predisposing catecholaminergic polymorphic ventricular tachycardia (CPVT).

88 ial arrhythmia catecholaminergic polymorphic ventricular tachycardia (CPVT).

89 T syndrome and catecholaminergic polymorphic ventricular tachycardia (CPVT).

90 ation (AF) and catecholaminergic polymorphic ventricular tachycardia (CPVT).

91 patients with catecholaminergic polymorphic ventricular tachycardia (CPVT; n=8) and in resuscitated

92 del of arrhythmic disease (catecholaminergic ventricular tachycardia; CPVT).

93 h ischemic cardiomyopathy and an ICD who had ventricular tachycardia despite antiarrhythmic drug ther

94 h ischemic cardiomyopathy and an ICD who had ventricular tachycardia despite the use of antiarrhythmi

95 eart block, bradycardia, supraventricular or ventricular tachycardia) developed.

96 ine support, markers of shock, recurrence of ventricular tachycardia, duration of mechanical ventilat

97 Following myocardial infarction, spontaneous ventricular tachycardia episodes (n = 3) were preceded b

98 Following myocardial infarction, spontaneous ventricular tachycardia episodes (n = 4) were preceded b

99 ion (14%), torsades de pointe or polymorphic ventricular tachycardia/fibrillation (6% [sustained 3%,

100 5 [0.67-0.82]) included presenting rhythm of ventricular tachycardia/fibrillation and pulseless elect

101 y composite end point of cardiac arrest from ventricular tachycardia/fibrillation or bradyarrhythmias

102 be improved by restricting witnessed SCDs to ventricular tachycardia/fibrillation or nonpulseless ele

103 sudden cardiac death (SCD) may be caused by ventricular tachycardia/fibrillation or pulseless electr

104 If only ventricular tachycardia/fibrillation witnessed cases (n=

105 Susceptibility to VT/VF (ventricular tachycardia/fibrillation) is difficult to pr

106 >=1 appropriate device therapies terminating ventricular tachycardia/fibrillation.

107 e had bidirectional ventricular tachycardia, ventricular tachycardia, frequent ventricular ectopy, an

108 or discharge for ventricular fibrillation or ventricular tachycardia >240 bpm) and 36 nonsudden cardi

109 plantable cardioverter-defibrillator treated ventricular tachycardia >250 beats per minute) in follow

110 art block; (3) ventricular fibrillation; (4) ventricular tachycardia (>15 beats); (5) atrial fibrilla

111 RV cardiomyopathy presenting with recurrent ventricular tachycardia, >10% increase in RV endocardial

112 hycardia and 4 patients with infarct-related ventricular tachycardia had unsuccessful response to rad

113 resistant ventricular fibrillation/pulseless ventricular tachycardia; however, the efficacy of AMD in

114 = 0.02), with the documentation of sustained ventricular tachycardia (HR 9.34; p = 0.001) and with th

115 odynamically tolerated sustained monomorphic ventricular tachycardia (HR: 2.19; p = 0.023), and male

116 g QT syndrome, catecholaminergic polymorphic ventricular tachycardia, hypertrophic cardiomyopathy, an

117 (including atrial fibrillation, nonsustained ventricular tachycardia, implantable cardiac defibrillat

118 d in 5 probands (age 15.3 +/- 1.9 years) and ventricular tachycardia in 10 (age 16.6 +/- 2.7 years),

119 The initiation of polymorphic ventricular tachycardia in long QT syndrome type 2 (LQT2

120 The BERLIN VT study (Preventive Ablation of Ventricular Tachycardia in Patients With Myocardial Infa

121 to innately induce transient post-transplant ventricular tachycardia in recent large animal model tra

122 at azithromycin can cause rapid, polymorphic ventricular tachycardia in the absence of QT prolongatio

123 nts presenting with left bundle branch block ventricular tachycardia in the setting of arrhythmogenic

124 elations that inform ablation strategies for ventricular tachycardia in these diseases.

125 d cells, (2) reduced adrenergically mediated ventricular tachycardia in treated mice, (3) reverted ul

126 t increased repolarization heterogeneity and ventricular tachycardia inducibility in perfused hearts.

127 explained syncope or of documented sustained ventricular tachycardia is associated with a higher risk

128 Post-infarct ventricular tachycardia is associated with channels of s

129 A common strategy for ablation of scar-based ventricular tachycardia is delivering multiple lesions i

130 Although the rate of idiopathic ventricular tachycardia is similar across sexes, women h

131 h of an isthmus/diastolic channel leading to ventricular tachycardia is unclear.

132 t or documented ventricular fibrillation and ventricular tachycardia (lasting >/=30 seconds or recurr

133 to the onset of ventricular fibrillation and ventricular tachycardia, leading to life-threatening arr

134 ice carrying a catecholaminergic polymorphic ventricular tachycardia-linked RyR2 mutation (A4860G) sh

135 nce of chronic renal disease or nonsustained ventricular tachycardia, low-income prescription benefit

136 Left posterior fascicular ventricular tachycardia (LPF-VT) is frequently misdiagno

137 ded age <30 days, CHD, vasoactive infusions, ventricular tachycardia, mechanical ventilation, sepsis,

138 ion, as in the catecholaminergic polymorphic ventricular tachycardia mice studies, or more generally

139 cardiac defibrillator shock (n=4), sustained ventricular tachycardia (n=1), or sudden death (n=1), co

140 , ventricular ectopy (n=10, 8 patients), and ventricular tachycardia (n=15, 13 patients).

141 ry direct ERT notification for 105 patients (ventricular tachycardia, n = 44; pause/asystole, n = 36;

142 ion was performed exclusively in 6 patients (ventricular tachycardia, n=1; PVC, n=5).

143 LV ablation was performed in 12 patients (ventricular tachycardia, n=2; PVC, n=10) and right ventr

144 In five patients with refractory ventricular tachycardia, noninvasive treatment with elec

145 The prognostic significance of nonsustained ventricular tachycardia (NSVT) in patients with hypertro

146 Nonsustained ventricular tachycardia (NSVT) is common after acute cor

147 , ventricular tachycardia (VT), nonsustained ventricular tachycardia (NSVT), and Lown's grade >=2 pre

148 syncope, atrial fibrillation, non-sustained ventricular tachycardia (nsVT), maximum left ventricular

149 atic event of multiple beats of nonsustained ventricular tachycardia (NSVT).

150 A reduction in episodes of ventricular tachycardia occurred in all five patients.

151 A 58-year-old woman presenting with a ventricular tachycardia of 190 beats/min was administere

152 high-quality evidence), and inducibility of ventricular tachycardia on electrophysiological study (5

153 iency profoundly decreased vulnerability for ventricular tachycardia on programmed right ventricular

154 Methods This study included 16 patients with ventricular tachycardia or frequent ventricular prematur

155 ias, including catecholaminergic polymorphic ventricular tachycardia or long QT syndrome and sudden c

156 ardiac arrest (OHCA) with initial rhythms of ventricular tachycardia or pulseless ventricular fibrill

157 atients meeting study criteria scheduled for ventricular tachycardia or PVC ablation over a 9-month p

158 Prompt defibrillation for IHCA caused by ventricular tachycardia or ventricular fibrillation was

159 Patients with IHCA caused by pulseless ventricular tachycardia or ventricular fibrillation were

160 itated arrest, successful defibrillation for ventricular tachycardia or ventricular fibrillation) wer

161 ular arrhythmias (non-sustained or sustained ventricular tachycardia or ventricular fibrillation).

162 Of 8119 patients with an IHCA caused by ventricular tachycardia or ventricular fibrillation, the

163 ients had a successful conversion of induced ventricular tachycardia or ventricular fibrillation.

164 electrical storm (ES), in which a cluster of ventricular tachycardias or ventricular fibrillation, ne

165 cause of ventricular fibrillation, pulseless ventricular tachycardia, or unknown shockable rhythm bet

166 plantable cardioverter-defibrillator treated ventricular tachycardia; or aborted SCD), syncope, 24-ho

167 lts with refractory ventricular fibrillation/ventricular tachycardia out-of-hospital cardiac arrest t

168 efractory ventricular fibrillation/pulseless ventricular tachycardia out-of-hospital cardiac arrest w

169 ECPR for refractory ventricular fibrillation/ventricular tachycardia out-of-hospital cardiac arrest.

170 ek blanking period, there were 4 episodes of ventricular tachycardia over the next 46 patient-months,

171 sease was associated with cardiac arrest and ventricular tachycardia (p = 0.02) and prevalence of PKP

172 Respiratory failure, persistent ventricular tachycardia, profound shock refractory to in

173 afterdepolarizations (EADs) and polymorphic ventricular tachycardias (PVTs).

174 T syndrome and catecholaminergic polymorphic ventricular tachycardia received routine beta-blocker th

175 tachycardia patients; however, a nontargeted ventricular tachycardia recurred in 1 patient at a media

176 tients post ablation, and 71% remain free of ventricular tachycardia recurrence at 6-month median fol

177 tion duration, 6-month sustained monomorphic ventricular tachycardia recurrence, quality of life meas

178 ncy ablation of the arrhythmic focus without ventricular tachycardia recurrence.

179 84) of patients had no sustained monomorphic ventricular tachycardia recurrence; the proportion of pa

180 ffective and safe therapies for scar-related ventricular tachycardias requires a detailed understandi

181 Notably, recurrent monomorphic ventricular tachycardia requiring >/=2 implantable cardi

182 o our institution with recurrent episodes of ventricular tachycardia requiring emergent total artific

183 as the composite of sudden cardiac death and ventricular tachycardia requiring treatment constituted

184 requent ventricular ectopy, and nonsustained ventricular tachycardia, respectively.

185 redistribution of gap junctions and promotes ventricular tachycardia, showing the functional signific

186 of ventricular tachycardia within 24 hours (ventricular tachycardia storm), or appropriate ICD shock

187 e of the composite primary outcome of death, ventricular tachycardia storm, or appropriate ICD shock

188 th 1; one (10%) patient died after incessant ventricular tachycardia storm, which led to terminal hea

189 CC causes a unique ventricular tachycardia substrate concentrated to the ba

190 al intramural and full thickness ablation of ventricular tachycardia substrate that is not accessible

191 and SCN5A) and catecholaminergic polymorphic ventricular tachycardia-susceptibility gene (RYR2) ident

192 osite end point of long runs of nonsustained ventricular tachycardia, sustained ventricular tachycard

193 Nonsustained ventricular tachycardia, syncope, a family history of su

194 , Brugada, and catecholaminergic polymorphic ventricular tachycardia syndromes) should also be consid

195 nificant advances in the ability to identify ventricular tachycardia termination sites through high-d

196 ases linked to catecholaminergic polymorphic ventricular tachycardia that feature lethal cardiac arrh

197 invasive electrocardiographic imaging during ventricular tachycardia that was induced by means of an

198 In 8 mapped reentrant ventricular tachycardias, the circuits included regions

199 mmed to high-rate cut-off (Arm B) or delayed ventricular tachycardia therapy (Arm C), compared with c

200 High-rate cut-off or delayed ventricular tachycardia therapy programming significantl

201 In idiopathic ventricular tachycardia, there was an increase in incide

202 for Endocardial RF Ablation in Patients With Ventricular Tachycardia [THERMOCOOL VT]; NCT00412607).

203 ployed this optical system in the setting of ventricular tachycardia to optimize mechanistic, multi-b

204 the morphologically distinctive polymorphic ventricular tachycardia ('torsades de pointes').

205 Catecholaminergic polymorphic ventricular tachycardia type 2 (CPVT2) results from auto

206 actory premature ventricular contractions or ventricular tachycardia underwent catheter cryoablation

207 15, five patients with high-risk, refractory ventricular tachycardia underwent treatment.

208 tients referred for ablation of scar-related ventricular tachycardia underwent voltage maps during a

209 ed age at diagnosis, documented nonsustained ventricular tachycardia, unexplained syncope, septal dia

210 ort each of pneumonia, pneumonia aspiration, ventricular tachycardia, upper gastrointestinal hemorrha

211 e, only the R67Q(+/-) mice had bidirectional ventricular tachycardia, ventricular tachycardia, freque

212 T-3), hypertrophic cardiomyopathy (HCM), and ventricular tachycardia-ventricular fibrillation (VT-VF)

213 ICD discharge-free survival for ventricular tachycardia/ventricular fibrillation >/= 240

214 /VAD); and 3) sudden cardiac death/sustained ventricular tachycardia/ventricular fibrillation (SCD/VT

215 unnecessary therapy but permits therapy for ventricular tachycardia/ventricular fibrillation (VF).

216 nging from frequent ectopy to pacing-induced ventricular tachycardia/ventricular fibrillation (VT/VF)

217 ICD termination of rapid ventricular tachycardia/ventricular fibrillation can rea

218 Patients with repetitive ventricular tachycardia/ventricular fibrillation episode

219 Each ES episode included a median of 7 ventricular tachycardia/ventricular fibrillation episode

220 strate reduces or prevents the recurrence of ventricular tachycardia/ventricular fibrillation in such

221 meet the primary end point of time to first ventricular tachycardia/ventricular fibrillation recurre

222 emales, determine whether ICD discharges for ventricular tachycardia/ventricular fibrillation were eq

223 in; p < 0.001) and less often presented with ventricular tachycardia/ventricular fibrillation, a witn

224 end point of time to death, ischemic stroke, ventricular tachycardia/ventricular fibrillation, and he

225 n = 44; pause/asystole, n = 36; polymorphic ventricular tachycardia/ventricular fibrillation, n = 14

226 wing events: cardiac death, ischemic stroke, ventricular tachycardia/ventricular fibrillation, or hea

227 nd point was the time to first recurrence of ventricular tachycardia/ventricular fibrillation.

228 ad non-ST-segment elevation MI, and 8.9% had ventricular tachycardia/ventricular fibrillation.

229 ienced appropriate interventions terminating ventricular tachycardia/ventricular fibrillation.

230 hythms of ventricular fibrillation/pulseless ventricular tachycardia (VF/pVT).

231 rhythms (ventricular fibrillation/pulseless ventricular tachycardia [VF/VT]) during resuscitation.

232 Outcomes of ventricular tachycardia (VT) ablation have been describe

233 ons most prone to reentry is needed to guide ventricular tachycardia (VT) ablation.

234 tion of patients with myocarditis undergoing ventricular tachycardia (VT) ablation.

235 ng the CARTOUNIVU module during scar-related ventricular tachycardia (VT) ablation.

236 utility of the GMC in creating substrate and ventricular tachycardia (VT) activation maps during VT a

237 Recurrence of ventricular tachycardia (VT) after ablation in patients

238 red tetralogy of Fallot die prematurely from ventricular tachycardia (VT) and sudden cardiac death.

239 enation during catheter ablation of unstable ventricular tachycardia (VT) at our center.

240 Radiofrequency ablation (RFA) of ventricular tachycardia (VT) can fail because of inacces

241 -hospital (OH) ventricular fibrillation (VF)/ventricular tachycardia (VT) cardiac arrest is unknown.

242 In vivo description of ventricular tachycardia (VT) circuits is limited by insu

243 ing awareness of the 3-dimensional nature of ventricular tachycardia (VT) circuits.

244 Postinfarction ventricular tachycardia (VT) generally involves myocardi

245 Ablation of postinfarction ventricular tachycardia (VT) has been shown to reduce VT

246 Inducibility of ventricular tachycardia (VT) has limited ability to pred

247 Various strategies for ablation of ventricular tachycardia (VT) have been described, but th

248 Catheter ablation of ventricular tachycardia (VT) in arrhythmogenic right ven

249 s catheter ablation of sustained monomorphic ventricular tachycardia (VT) in LMNA cardiomyopathy.

250 Catheter ablation (CA) of ventricular tachycardia (VT) in patients with cardiac sa

251 f data regarding radiofrequency ablation for ventricular tachycardia (VT) in patients with cardiogeni

252 Catheter ablation (CA) of ventricular tachycardia (VT) in patients with nonischemi

253 Background Catheter ablation of ventricular tachycardia (VT) in structural heart disease

254 n of arrhythmias during catheter ablation of ventricular tachycardia (VT) in structurally abnormal he

255 Ventricular tachycardia (VT) is a major cause of sudden

256 Catheter ablation of ventricular tachycardia (VT) is being increasingly perfo

257 ients with ischemic cardiomyopathy (ICM) and ventricular tachycardia (VT) is important for understand

258 potential (LP) abolition and postprocedural ventricular tachycardia (VT) noninducibility is known to

259 l abnormal ventricular activities (LAVA) and ventricular tachycardia (VT) noninducibility.

260 The end point was the first event of ventricular tachycardia (VT) or fibrillation (VF).

261 or catheter ablation procedure for sustained ventricular tachycardia (VT) or nonsustained VA with ass

262 Ventricular tachycardia (VT) radiofrequency ablation has

263 Catheter ablation for ventricular tachycardia (VT) reduces the recurrence of V

264 ial structural and functional changes in the ventricular tachycardia (VT) substrate.

265 are often short with multiple side branches, ventricular tachycardia (VT) supporting channels have ve

266 In contrast to ventricular tachycardia (VT) that occurs in the setting

267 guided noninvasive cardiac radioablation for ventricular tachycardia (VT) using stereotactic body rad

268 Polymorphic ventricular tachycardia (VT) without QT prolongation is

269 To facilitate ablation of ventricular tachycardia (VT), an automated localization

270 ment (LGE), (2) quantify their risk of death/ventricular tachycardia (VT), and (3) identify imaging-b

271 ization, including ventricular fibrillation, ventricular tachycardia (VT), nonsustained ventricular t

272 In infarct-related ventricular tachycardia (VT), the circuit often correspo

273 ight ventricular pathological remodeling and ventricular tachycardia (VT).

274 catheter ablation is used to treat recurrent ventricular tachycardia (VT).

275 ions in the CACNA1C gene are associated with ventricular tachycardia (VT).

276 lico approach for simulating infarct-related ventricular tachycardia (VT).

277 reduced the susceptibility to develop acute ventricular tachycardia (VT).

278 y (SBRT) is a novel treatment for refractory ventricular tachycardia (VT).

279 annels defined in electroanatomic mapping in ventricular tachycardia (VT).

280 ere enrolled: 63 (group 1) having documented ventricular tachycardia (VT)/ventricular fibrillation (V

281 ts (8%) without NSVT experienced ICD-treated ventricular tachycardia (VT)/ventricular fibrillation (V

282 ized proarrhythmic substrate for postinfarct ventricular tachycardias (VT) identifiable on contrast-e

283 on therapy ICDs, history of >/=1 ICD-treated ventricular tachycardias (VT)/ventricular fibrillation e

284 ntricular ectopy >=5%), most often moderate (ventricular tachycardia [VT]; 120 to 179 beats/min) in 2

285 Fast ventricular tachycardias (VTs) have historically been at

286 heters has expanded the spectrum of mappable ventricular tachycardias (VTs).

287 mposite incidence of sudden cardiac death or ventricular tachycardia was 41% at 1 year and 55% at 5 y

288 probability of catecholaminergic polymorphic ventricular tachycardia was determined for all RYR2-posi

289 The diastolic isthmus in ventricular tachycardia was mapped in 3 patients and col

290 Ventricular tachycardia was noninducible in 85% of patie

291 thm of ventricular fibrillation or pulseless ventricular tachycardia was refractory to shock.

292 sinus tachycardia, atrial fibrillation, and ventricular tachycardia were found to be the most common

293 omyopathy, and catecholaminergic polymorphic ventricular tachycardia were the most common diagnoses.

294 ith large pleural effusions and another with ventricular tachycardia, were not successfully gated.

295 d ablation of right ventricular scar-related ventricular tachycardia with computed tomographic image

296 ythmia syndrome characterized by polymorphic ventricular tachycardia with physical or emotional stres

297 icular fibrillation and those with sustained ventricular tachycardia with syncope or systolic heart f

298 death, three or more documented episodes of ventricular tachycardia within 24 hours (ventricular tac

299 shocks triggered at heart rates >/= 170 bpm (ventricular tachycardia zone) and at rates >/= 200 bpm (

300 that restrict therapy to regular rhythms in ventricular tachycardia zones.